---
title: "Acetyl Hexapeptide-8"
canonical_url: https://peptidelibrary.app/library/acetyl-hexapeptide-8
description: "Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Acetyl Hexapeptide-8

Acetyl Hexapeptide-8 (also called Argireline or Acetyl Hexapeptide-3) is a cosmetic SNARE-targeting peptide. Acetyl hexapeptide-8, commonly sold as Argireline, mimics the N-terminal sequence of SNAP-25, one of the three SNARE proteins that assemble to fuse neurotransmitter vesicles with the presynaptic membrane.

Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug.

Also known as: Argireline, Acetyl Hexapeptide-3.

Categories: Cosmetic, Experimental.

## Classification

- Type: Cosmetic SNARE-targeting peptide
- Mechanism class: SNARE-pathway cosmetic peptide
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Acetyl hexapeptide-8, commonly sold as Argireline, mimics the N-terminal sequence of SNAP-25, one of the three SNARE proteins that assemble to fuse neurotransmitter vesicles with the presynaptic membrane. By competing for a position in the SNARE complex it is reported to destabilise assembly, reducing calcium-dependent catecholamine and acetylcholine release in model systems. The intended cosmetic consequence is reduced contraction of facial expression muscles and therefore softened dynamic lines — a mechanism conceptually parallel to botulinum toxin, which cleaves SNAP-25 enzymatically, but far weaker and non-enzymatic. The central open question is topical delivery: a hydrophilic hexapeptide penetrates intact stratum corneum poorly, and most supporting data comes from small formulation studies.

Targets: SNAP-25 / SNARE complex.

Origin: Synthetic acetylated hexapeptide used as a cosmetic active.

## Properties

- Sequence: Glu-Glu-Met-Gln-Arg-Arg
- Length: 6
- Molecular formula: Varies by salt/hydration (see PubChem/INCI)
- CAS number: 616204-22-9
- Half-life: Topical; systemic PK not established
- Studied routes: Topical

## Evidence

- Evidence level: Limited Human Evidence
- Highest documented: Controlled human trials
- Human trials: 4
- Controlled human trials: 4
- Preclinical sources: 1
- Latest source: 2023

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. Wang Y et al. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013. 2013. Controlled human trial. Population: 60 Chinese adults with periorbital wrinkles, randomised 3:1 to argireline or placebo. Subjective anti-wrinkle efficacy 48.9% with argireline vs 0% with placebo; skin-replica roughness parameters fell with argireline (p < 0.01) but not with placebo [Source](https://pubmed.ncbi.nlm.nih.gov/23417317/)
2. NCT00942851 — A Study of Acetyl Hexapeptide-8 (AH8) in Treatment of Blepharospasm. Controlled human trial. Population: 24 people with blepharospasm (focal dystonia); the registry describes benefit as added to botulinum toxin injection. Posted mean time until the Jankovic Blepharospasm Rating Scale returned to baseline: 3.71 months with AH-8 vs 3.03 months with placebo [Source](https://clinicaltrials.gov/study/NCT00942851)
3. NCT01750346 — Acetyl Hexapeptide-8 for Blepharospasm. Controlled human trial. Population: 8 people with blepharospasm (focal dystonia) in three arms. Posted Jankovic Blepharospasm Rating Scale at 2 months: 6 (0.05%), 7 (0.025%) and 4.33 (placebo) [Source](https://clinicaltrials.gov/study/NCT01750346)
4. NCT01381484 — Argireline in Treatment of Periorbital Wrinkles. Human study (early or uncontrolled). Population: 70 adults with periorbital wrinkles (actual enrolment). No results posted on the registry. Limitations: Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT01381484)
5. Aruan RR et al. Double-blind, Randomized Trial on the Effectiveness of Acetylhexapeptide-3 Cream and Palmitoyl Pentapeptide-4 Cream for Crow's Feet. J Clin Aesthet Dermatol. 2023. 2023. Controlled human trial. Population: 21 Indonesian women aged 26–55 with crow's feet, split into three groups: acetylhexapeptide-3 cream, palmitoyl pentapeptide-4 cream and placebo. Improvements in several subjects with both creams; the authors reported better results with palmitoyl pentapeptide-4 than with acetylhexapeptide-3 (another INCI name for this peptide) and called it an initial study needing more subjects [Source](https://pubmed.ncbi.nlm.nih.gov/36909866/)
6. Kraeling ME et al. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015. 2015. Preclinical: in vitro (cells or tissue). Population: Human cadaver skin and hairless guinea pig skin in diffusion cells. Most peptide washed off the surface; 0.22% of the applied amount stayed in human stratum corneum and 0.01% reached the epidermis; none was detected in the dermis or the fluid below the skin. Limitations: Lab or animal research: not evidence of a human effect or dose. [Source](https://pubmed.ncbi.nlm.nih.gov/24754410/)

### Registered trials

- [NCT00942851](https://clinicaltrials.gov/study/NCT00942851)
- [NCT01750346](https://clinicaltrials.gov/study/NCT01750346)
- [NCT01381484](https://clinicaltrials.gov/study/NCT01381484)

## Safety

Side effects: Mild irritation; Redness; Contact dermatitis (uncommon).

Risks: Not a medical botulinum alternative; Cosmetic-grade products vary in concentration.

Human safety basis: Limited human reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Acetyl Hexapeptide-8 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Permitted
- Availability: OTC / Supplement

## Frequently asked questions

### What is Acetyl Hexapeptide-8?

Topical hexapeptide (Argireline) used in cosmetics as a SNAP-25 fragment analog. Marketed to soften expression lines; not an FDA-approved drug.

### How does Acetyl Hexapeptide-8 work?

Acetyl hexapeptide-8, commonly sold as Argireline, mimics the N-terminal sequence of SNAP-25, one of the three SNARE proteins that assemble to fuse neurotransmitter vesicles with the presynaptic membrane. By competing for a position in the SNARE complex it is reported to destabilise assembly, reducing calcium-dependent catecholamine and acetylcholine release in model systems.

### Is Acetyl Hexapeptide-8 FDA approved?

No. Acetyl Hexapeptide-8 is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Acetyl Hexapeptide-8?

Reported half-life for Acetyl Hexapeptide-8 is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### What is the amino acid sequence of Acetyl Hexapeptide-8?

Acetyl Hexapeptide-8 has the sequence Glu-Glu-Met-Gln-Arg-Arg, giving a chain of 6 amino acids. Its molecular formula is Varies by salt/hydration (see PubChem/INCI).

### Is Acetyl Hexapeptide-8 banned in sport?

Acetyl Hexapeptide-8 is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

## References

- [PubChem Argireline](https://pubchem.ncbi.nlm.nih.gov/compound/Argireline)
- [The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study — Am J Clin Dermatol, 2013](https://pubmed.ncbi.nlm.nih.gov/23417317/)
- [Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy — Int J Mol Sci, 2025](https://pubmed.ncbi.nlm.nih.gov/40565185/)
- [Cosmeceuticals in photoaging: A review — Skin Res Technol, 2024](https://pubmed.ncbi.nlm.nih.gov/39233460/)
- [The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture: Ex vivo and clinical studies — Int J Cosmet Sci, 2026](https://pubmed.ncbi.nlm.nih.gov/41668671/)
- [Acetyl Hexapeptide-8 as a Topical Alternative to Botulinum Toxin: A Review of the Literature — J Drugs Dermatol, 2025](https://pubmed.ncbi.nlm.nih.gov/40196949/)
